Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report

BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement is a key oncogenic driver promoting the expression of ALK protein in non-small cell lung cancer (NSCLC). ALK tyrosine kinase inhibitors (TKIs) have significantly improved survival benefits. However, the emergence of drug resistance limits th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Han, Dai, Hui, Ding, Liren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459556/
https://www.ncbi.nlm.nih.gov/pubmed/36093526
http://dx.doi.org/10.21037/tcr-21-2838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459556/
https://www.ncbi.nlm.nih.gov/pubmed/36093526
http://dx.doi.org/10.21037/tcr-21-2838

Ejemplares similares